About this item:

30 Views | 15 Downloads

Author Notes:

Haimanot Wasse, MD, MPH, Emory University School of Medicine, Renal Division, Woodruff Memorial Research Building, Room 338,1639 Pierce Dr., Atlanta, GA 30322; Phone: 404-727-1598; Fax: 404-727-3425; hwasse@emory.edu

Authors had no disclosures.

Subjects:

Research Funding:

This study was supported by a University Research Committee Grant, Emory University (H.W.); an NIH K23 DK65634 (H.W.); and a PHS Grant (UL1 RR02008, KL2 RR025009 or TL1 RR025010, and UL1TR000454) from the Clinical and Translational Science Award Program, National Institutes of Health, National Center for Research Resource

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Peripheral Vascular Disease
  • Cardiovascular System & Cardiology
  • AVF
  • Dialysis access
  • ESRD
  • Vitamin D
  • SMOOTH-MUSCLE-CELLS
  • VITAMIN-D ANALOGS
  • PLASMINOGEN-ACTIVATOR INHIBITOR-1
  • CONGESTIVE-HEART-FAILURE
  • HEMODIALYSIS-PATIENTS
  • 25-HYDROXYVITAMIN D-3-1-ALPHA-HYDROXYLASE
  • INCREASED EXPRESSION
  • PARATHYROID-HORMONE
  • ENDOTHELIAL-CELLS
  • OXIDATIVE STRESS

Very high-dose cholecalciferol and arteriovenous fistula maturation in ESRD: a randomized, double-blind, placebo-controlled pilot study

Tools:

Journal Title:

Journal of Vascular Access

Volume:

Volume 15, Number 2

Publisher:

, Pages 88-94

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Purpose: While vitamin D is critical for optimal skeletal health, it also appears to play a significant role in vascular homeostasis. This pilot study compared arteriovenous (AV) access outcomes following cholecalciferol supplementation compared to placebo in end-stage renal disease patients preparing to undergo AV access creation. Methods: A total of 52 adult hemodialysis patients preparing for arteriovenous fistula (AVF) creation were randomized to receive perioperative high-dose cholecalciferol versus placebo in this double-blind, randomized, placebo-controlled pilot study. The primary outcome was mean response to high-dose oral cholecalciferol versus placebo, and secondary outcome AV access maturation at 6 months. Logistic regression was used to assess the association between AV access maturation and baseline, posttreatment and overall change in vitamin D concentration. Results: A total of 45% of cholecalciferol-treated and 54% of placebo-treated patients were successfully using their AVF or arteriovenous graft (AVG) at 6 months (p=0.8). Baseline serum concentrations of 25(OH)D and 1,25(OH)2D did not differ between those who experienced AVF or AVG maturation and those who did not (p=0.22 and 0.59, respectively). Similarly, there was no relationship between AVF or AVG maturation and posttreatment serum 25(OH)D and 1,25(OH)2D concentration (p=0.24 and 0.51, respectively). Conclusions: Perioperative high-dose vitamin D3 therapy does correct 25(OH)D level but does not appear to have an association with AV access maturation rates. Future research may include extended preoperative vitamin D3 therapy in a larger population or in certain subpopulations at high risk for AVF failure.

Copyright information:

© 2014 Wichtig Publishing.

Export to EndNote